Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study - Zhao, Peng; An, Zhuo‐Yu; Fu, Hai‐Xia; Liu, Hui‐Xin; Feng, Cheng‐Jie; Huang, Qiu‐Sha; Wu, Jin; Wu, Ye‐Jun; Yang, Li‐Ping; Qu, Qing‐Yuan; Chen, Yu‐Xiu; Li, Meng‐Lin; et al. (American journal of hematology, 2024)
Keywords: Adult; Adverse events; Aged; Autoimmune diseases; Azetidines - administration & dosage; Azetidines - adverse effects; Azetidines - therapeutic use; Corticosteroids; Drug Resistance; Female; Humans; Idiopathic thrombocytopenic purpura; Male; Middle Aged; Pilot Projects; Platelet Count; Platelets; Purines - administration & dosage; Purines - adverse effects; Purines - therapeutic use; Purpura, Thrombocytopenic, Idiopathic - drug therapy; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Quality of life; Recurrence; Steroids; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Thrombocytopenia; Treatment Outcome